Whalesbook
Arey bhai, suno! India ki pharma exports ka scene abhi kaafi complicated ho gaya hai.
Middle East mein situation thodi normal ho rahi hai, but isse hamari drug export karne wali companies ki tension kam nahi hui. Global supply chain ka drama abhi bhi chal raha hai. Experts keh rahe hain ki freight charges double ho gaye hain, matlab maal bhejne ka kharcha kaafi badh gaya hai. Aur toh aur, hum log imported drug ingredients (APIs) ke liye bhi dusre countries pe depend karte hain, especially China pe. Isliye, sab theek hone mein abhi kuch mahine lag sakte hain. Jo companies pehle hi mehange raw materials khareed chuki hain, unke liye prices kam hone ki ummeed bhi kam hai. West Asia, jo hamare liye kaafi important market hai, wahan bhi pharma exports pe ₹2,500 se ₹5,000 crore tak ka nuksan ho sakta hai agar yeh situation aage chalti rahi. Yeh crisis dikha raha hai ki humein apni supply chain ko aur strong banana padega aur desh mein hi APIs banane pe zyada focus karna hoga.
West Asia India ke pharma exports ke liye ek bada market hai, lagbhag 5.6% export wahi jata hai. UAE, Saudi Arabia, Oman jaise countries humse affordable generic medicines mangwate hain. Lekin abhi jo shipping routes disrupt ho gaye hain aur freight costs itne badh gaye hain, usse exporters ko bahut mushkil ho rahi hai. Sunne mein aaya hai ki freight charges do-gune ho gaye hain, aur extra charges $4,000 se $8,000 tak lag rahe hain per shipment. Pharmexcil ka andaaza hai ki agar March tak yeh sab chalta raha toh industry ko ₹2,500 crore se ₹5,000 crore ($300-$600 million) ka nuksan ho sakta hai. Isse companies ke profits pe pressure aa raha hai, aur payments bhi late ho rahi hain. Kaafi tension hai bhai!
Ab ek aur bada panga hai: hum log Active Pharmaceutical Ingredients (APIs) aur Key Starting Materials (KSMs) ke liye bahut zyada bahar se maal mangwate hain. Lagbhag 70% tak ke zaroori drug components India ke bahar se aate hain, mostly China se. China ki mass production ki wajah se wahan sab kuch sasta milta hai. Jab bhi duniya mein koi gadbad hoti hai, toh China ki supply chain pe asar padta hai, aur woh seedha humein affect karta hai. India ko "Pharmacy of the World" kehte hain kyunki hum duniya mein sabse zyada generics banate hain (20% globally), but value ke hisaab se rank thoda neeche hai. Yeh cost-focused model China pe bahut depend karta hai. COVID-19 jaise past disruptions ne sikha diya hai ki change zaroori hai. Ab government ki Production Linked Incentive (PLI) scheme aur Bulk Drug Parks banane ki plans isi liye hain taaki desh mein API production badhe aur hum import pe kam depend karein. Yeh ab aur bhi zaroori ho gaya hai, warna aise hi phashte rahenge.
Ab export mein issues chal rahe hain, but overall pharma sector mein steady growth expected hai. ICRA keh raha hai ki FY2026 mein revenue 7-9% badh sakta hai, jismein domestic demand aur Europe ke exports ka contribution hoga. US market mein thoda slow growth ho sakta hai prices aur regulatory issues ki wajah se. Duniya bhar mein bhi medicine spending mein mid-single-digit growth ki ummeed hai 2026 ke liye, thanks to innovation. Lekin policy uncertainty aur supply chains ko regional banane ki koshish profits ko affect kar sakti hai. Haal hi mein EU-India trade pact se Europe mein exports ko fayda mil sakta hai tariffs kam hone se. Phir bhi, geopolitical risks, supply chain problems, aur higher-value products (like biologics) mein innovation ki zaroorat bani hui hai. Focus ab sirf kam cost se hatt kar quality, reliability, aur supply chain strength pe ja raha hai. Is change ke liye kaafi investment aur collaboration chahiye hoga.
West Asia mein jo conflict chal raha hai, woh India ki pharma industry ke liye ek big test hai. Yeh sirf shipping ki temporary problem nahi, balki systemic risks dikha raha hai. Sabse badi problem hai China se API aur KSMs import karne pe humara heavy reliance. Jab hum sirf ek country pe itna depend karte hain, toh finished medicines India mein banne ke baad bhi upstream supply chain exposed rehti hai. China ka scale aur government support unhein bahut kam prices offer karne mein help karta hai, jiski wajah se India mein domestic API production kabhi develop hi nahi ho payi. Upper se, volume aur cost pe focus karne ke chakkar mein quality aur regulatory compliance pe kabhi kabhi kam dhyan diya gaya, jiski wajah se FDA warning letters jaise issues aaye. Ab jab global tensions hain, energy aur shipping costs badh gaye hain, toh risks aur badh gaye hain. Isse drug shortages aur price swings ka chance badh gaya hai. Self-reliant banne ke liye PLI schemes important hain, but inko effective hone mein time aur paisa lagega, especially jab global competition bhi bahut hai.
India ki pharma industry, jo 2030 tak $130 billion ki ho jayegi, woh ek crucial point pe hai. Exports mein resilience dikhi hai, February FY26 tak $29 billion tak pahunch jayenge, but industry ko apne strategic changes fast karne honge. Aage ka path do cheezon pe depend karta hai: APIs aur KSMs ka domestic production 80-90% tak badhana, aur export markets aur shipping routes ko diversify karna taaki geopolitical aur supply chain disruptions ka impact kam ho. Analysts sector ke liye stable outlook de rahe hain, growth innovation, higher-value products, aur government support se aayegi. Lekin apni global leadership maintain karne ke liye, India ko sirf competitive prices dene se aage badh kar quality, reliability, aur strong supply chain resilience mein leader banna hoga. Abhi toh situation critical hai, dekhte hain kya hota hai.